Staff

Mark Roithmayr is Chief Executive Officer, and his primary focus is securing the resources needed to find effective drugs for Alzheimer's disease. Mr. Roithmayr is a seasoned nonprofit executive with experience in both start-ups and mature organizations. His areas of expertise include strategic planning, fundraising, volunteer development, and brand-building.

Mr. Roithmayr was previously Chief Relationship Officer at the Leukemia and Lymphoma Society. There, he helped launch its venture philanthropy initiative, directed its 56 national chapters, and led annual fundraising of over $200 million. Prior to joining the Leukemia and Lymphoma Society in 2013, he served for seven years as president of Autism Speaks. As that organization's first president, he shepherded its growth from a start-up into the world's largest autism research and advocacy organization. During his tenure, Autism Speaks invested more than $170 million in research, resulting in discoveries about the genetic and environmental factors that lead to autism as well as effective treatments for it. Earlier in his career, Mr. Roithmayr held several executive positions with the March of Dimes. He earned a bachelor's degree in communications at Rowan University.

Lauren Friedman, PhD, supports the management of our drug discovery portfolio by providing scientific and strategic review of preclinical drug discovery proposals and tracking program progress. Dr. Friedman also manages the ADDF ACCESS program, which provides a virtual network of contract research organizations (CRO) and consultants and offers educational resources on drug discovery and CRO selection and management.

Dr. Friedman completed her postdoctoral training at Columbia University, where she studied modulators of autophagy in Alzheimer's disease. She earned a doctorate in neuroscience at the Icahn School of Medicine at Mount Sinai, where she focused on molecular mechanisms underlying the development and degeneration of brain circuits involved in autism and Parkinson's disease. She received a bachelor's degree in biopsychology from Tufts University. Dr. Friedman has authored numerous peer-reviewed publications and is a member of the Society for Neuroscience, New York Academy of Sciences and the Association for Women in Science.

Yuko Hara, PhD, is a member of the ADDF’s Aging and Alzheimer's Prevention team. In this capacity, she critically evaluates the scientific evidence behind therapies to promote brain health and/or prevent Alzheimer's disease. She also investigates potential risk factors as well as research proposals on prevention therapies.

Dr. Hara was previously an Assistant Professor in Neuroscience at the Icahn School of Medicine at Mount Sinai, where she remains an adjunct faculty member. Her research focused on brain aging, specifically how estrogens and reproductive aging influence the aging brain’s synapses and mitochondria. She earned a doctorate in neurology and neuroscience at Weill Graduate School of Medical Sciences of Cornell University and a bachelor's degree in biology from Cornell University, with additional study at Keio University in Japan. Dr. Hara has authored numerous peer-reviewed publications, including articles in PNAS and Journal of Neuroscience.

Andrew Koemeter-Cox, PhD, works on the ADDF’s scientific initiatives, including the ACCESS program. In this capacity, he assists with reviews of funding proposals and manages the ACCESS website, which connects researchers with CROs and other drug discovery expertise.

Dr. Koemeter-Cox was most recently a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, where he studied the epigenetics of axon regeneration in the context of spinal cord injury. From 2007 until 2009, he was a research technician with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), assisting with studies on neuroprotection strategies. Dr. Koemeter-Cox earned a doctorate in biomedical science from The Ohio State University College of Medicine and a bachelor’s degree in biochemistry from the University of Delaware. He is a member of the New York Academy of Sciences, where he serves as a mentor for several programs. 

Nick McKeehan is a member of the ADDF's Aging and Alzheimer's Prevention program. He evaluates the scientific evidence for and against therapies to promote brain health and/or prevent Alzheimer's disease at our website CognitiveVitality.org and contributes regularly to the site's blog.

Mr. McKeehan previously served as Chief Intern at Mid Atlantic Bio Angels (MABA) and was a research technician at Albert Einstein College of Medicine investigating repair capabilities of the brain. Mr. McKeehan received a bachelor of science degree in biology from Purdue University, where he was awarded a Howard Hughes Scholarship. He also writes about the biotechnology industry for 1st Pitch Life Science.

Ethan Hutchinson directs the ADDF's finance and adminstrative staff. He brings more than 25 years of experience in business finance to this role. Mr. Hutchinson began his career at a NYC-based management consulting firm with more than 100 clients representing a variety of industries both domestic and international.

During his career, he developed specialized expertise in software development and online media, working with diverse clients including Network-1 Security Solutions, Inc., Medium4.com and DailyCandy, Inc. Mr. Hutchinson collaborates directly with founders to help organizations like these grow from inception into success stories. He received his undergraduate degree from the University of Hartford.

Rochelle Bloom serves as a consultant advising the ADDF on brand, marketing, and partnerships. From 2003 to 2011, she served as President of the Fragrance Foundation. Prior to her tenure there, Mrs. Bloom was President of Bobbi Brown Cosmetics, where she utilized her marketing and management expertise to maximize the potential of the prestige cosmetic brand on a global basis.

She has held several senior positions at Estée Lauder Inc. Mrs. Bloom joined the company as a Marketing Director for Estée Lauder Canada and rose to become Senior Vice President/General Manager of Estée Lauder International, a position she flourished in for 13 years, tripling sales and quadrupling profits. She has advised numerous organizations, including Pratima Ayurvedic Skincare, LaserLock Technologies Inc., and the Fashion Institute of Technology's Master's Degree program, where she was also a faculty member. Mrs. Bloom is a former Board member of the Women's Forum, the Harper's BAZAAR anti-counterfeiting alliance, and the Alumni Board of Harvard Business School. She holds a bachelor's degree in economics from Syracuse University and completed the Advanced Management Program at Harvard Business School.

Krishna Knabe leads the marketing and communications team, which includes media relations, marketing and advertising, design, and editorial functions. She has more than 15 years of strategic communications experience, with a focus on developing and implementing successful brand and content strategies for nonprofit organizations. Before joining the Alzheimer’s Drug Discovery Foundation, she was Director of Communications for the International Center of Photography (ICP). During her tenure, she created and led digital campaigns that garnered coverage in the Wall Street Journal and other publications and resulted in substantial growth of ICP’s online audiences. From 2007 to 2013, Ms. Knabe managed communications at the William T. Grant Foundation, a leading funder of research to improve the lives of American youth. Her experience also includes marketing and editorial roles at major educational and arts institutions as well as national and regional publications.

Ms. Knabe earned a master’s of science in strategic communications from Columbia University and a bachelor of arts from the University of Chicago.